Article Sidebar

PDF
Date Published: 17/02/2023
Abstract Views: 273
Views PDF: 127
DOI: https://doi.org/10.51298/vmj.v520i2.4130
Issue
Vol. 520 No. 2 (2022)
Section
Các bài báo
How to Cite
Nguyễn, H. M. D., Nguyễn, C. Đức H. ., Hồ, T. T. H., Võ, N. Y. N., & Nguyễn, T. T. T. . (2023). CONSTRUCT THE MODEL OF COST– EFFECTIVENESS ANALYSIS OF DARATUMUMAB VERSUS STANDARD THERAPY IN THE TREATMENT OF MULTIPLE MYELOMA IN VIETNAM. Vietnam Medical Journal, 520(2). https://doi.org/10.51298/vmj.v520i2.4130

CONSTRUCT THE MODEL OF COST– EFFECTIVENESS ANALYSIS OF DARATUMUMAB VERSUS STANDARD THERAPY IN THE TREATMENT OF MULTIPLE MYELOMA IN VIETNAM

Huỳnh Mỹ Duyên Nguyễn1, Cao Đức Huy Nguyễn1, Thị Thanh Huyền Hồ1, Ngọc Yến Nhi Võ, Thị Thu Thủy Nguyễn1,
1 University of Medicine and Pharmacy at Ho Chi Minh City hospital

Main Article Content

Abstract

Daratumumab was approved by the Food and Drug Administration (FDA) in 2015 in the treatment of multiple myeloma [3] and its clinical efficacy has been confirmed through many studies around the world [6]. However, cost-effectiveness is a factor to consider when prescribing drugs in clinical practice, especially in countries with limited health budgets like Vietnam. In cost-effectiveness analysis, model building is an important step, especially since no research has been conducted in Vietnam. With the modeling method, the cost – effectiveness analysis model has been built based on Microsoft Excel 2013 software with model structure. The model allows evaluating the cost – effectiveness of daratumumab versus standard therapy in treating multiple myeloma in Vietnam.

Article Details

Keywords

Cost – effectiveness, model, daratumumab, multiple myeloma.

References

1. Cao Y, Zhao L, Zhang T, et al (2021), Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma. Front Pharmacol, pp. 608-685.
2. Carlson J. J. et al. (2018), "Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States", J Manag Care Spec Pharm. 24 (1), pp. 29-38.
3. FDA (2021), "FDA approves daratumumab and hyaluronidase-fihj with pomalidomide and dexamethasone for multiple myeloma", https://www.fda.gov, 07/12/2021. [Online]. Available: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-pomalidomide-and-dexamethasone-multiple-myeloma. [Accessed: 06/08, 2021].
4. Gong CL, Studdert AL, Liedtke M, (2019), Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis. Am J Hematol, 94(3), pp. 68-70.
5. Landgren O, Kyle RA, Pfeiffer RM, et al (2009), Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood, 113(22), pp. 5412- 5417.
6. McKeage, K (2016).. Daratumumab: First Global Approval. Drugs 76, pp. 275–281.
7. Patel K. K. et al. (2021), "Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma", J Clin Oncol. 39 (10), pp. 1119-1128.
8. Pelligra C. G. et al. (2017), "Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States", Clin Ther. 39 (10), pp. 1986-2005.e1985.
9. SiNi Li, JianHe Li, LiuBao Peng, ChongQing Tan, XiaoHui Zeng, CiYan Peng, Chang Zhang, YaMin Li, XiaoMin Wan, (2021), First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis, Clinical Therapeutics, ISSN 0149-2918.
10. Zeng X, Peng L, Peng Y, Tan C, Wan X, (2020), Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR. Clin Ther;42(2), pp. 251-262.
11. Zeng X, Liu Q, Peng L, et al (2021), Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma. Adv Ther, 38(5), pp. 2379-2390.